The Radiation Oncology Division, in collaboration with the Maine Medical Center Department of Radiation Oncology and the Maine Medical Center Research Institute, is proud to have 24 clinical trials available to offer our patients. The studies allow patients with a broad range of malignancies to participate in cutting edge, practice-changing research close to home. Our program is very active, and during the past year we enrolled 48 patients in these studies. We have been a national accrual leader to both the Dana Farber Cancer Institute FABREC trial (hypofractionated vs. standard post-mastectomy radiation therapy after reconstruction) and the NRG CC007CD trial (investigates the role of survivorship care planning in prostate cancer) with 11 and 19 patients respectively last year alone.
We have recently added four new phase-three trials to our portfolio about which we are particularly excited: the ECOG-ACRIN’s EA8191 INDICATE and EA2174 trials, and NRG Oncology’s GU009 PREDICT-RT and BN007 trials. EA8191 is investigating the role of concurrent and adjuvant immunotherapy in locally advanced esophageal adenocarcinoma. INDICATE evaluates the benefit of advanced imaging and escalated systemic therapy in concert with radiation therapy for men with biochemical recurrence after radical prostatectomy. PREDICT-RT looks at utilizing a genomic classifier to escalate or de-escalate therapy for men with high-risk prostate cancer. BN007 is comparing standard chemotherapy vs. immunotherapy in combination with radiation therapy for glioblastoma. It is very likely that the results of all of these trials will be practice changing and we are proud to play a role in moving the field forward and improving outcomes for Mainers with cancer in the future.
